The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIlika Plc Regulatory News (IKA)

Share Price Information for Ilika Plc (IKA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 28.50
Bid: 28.00
Ask: 29.00
Change: 0.00 (0.00%)
Spread: 1.00 (3.571%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 28.50
IKA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half Yearly Report

22 Jan 2015 07:00

RNS Number : 8017C
Ilika plc
22 January 2015
 



 

Ilika plc

('Ilika,' the 'Company,' or the 'Group')

 

Half Yearly Report

 

Ilika (AIM: IKA), the accelerated materials innovation company, announces its unaudited half yearly report for the six months ended 31 October 2014, a period of continued progress with its solid state battery development programme, increased commercial interactions with its global customer base and strengthening of its IP portfolio.

 

Ilika accelerates the discovery of new and patentable materials using its unique high throughput technologies process for identified end uses in the energy, electronics, and aerospace sectors.

 

Operational Highlights

· Grant of two patents covering methods for producing solid state batteries

· 25 x increase in solid state battery size

· Proof of concept contract win with European partner for development of batteries for wireless sensor networks

· Keith Jackson, CTO of Meggitt plc, appointed as NED to the board

· Successful factory acceptance test of £3.3m pilot production line

 

Post Period End Events

· Official opening of pilot line by Rt. Hon Greg Clark MP

· 20 x larger deposition area of key battery materials

· 5 x increase in materials deposition rate

 

Financial Summary

· Total revenue for the period at £0.6m is in line with prior period (1H 2013: £0.6m)

· Loss per share has reduced to 2p (1H 2013: 3p per share)

· Net cash inflow in the period £0.1m (1H 2013: outflow £1.7m)

· Cash balance at period end £7.3m (1H 2013: £1.4m)

 

Commenting on the results Graeme Purdy, CEO of Ilika, said: "Ilika has continued to maintain both commercial and technical momentum since the exciting announcement in January of 2014 of its "world's first" for the fabrication of a solid state battery that can be manufactured as a continuous stack. By the summer of 2014, we were able to fabricate significantly larger batteries on a footprint that is commercially relevant for our initial target markets.

 

"Commercial interest has been strong from the leading players in sensor network technology as well as global OEM's, which are investing heavily in wearable technology. The remainder of this year will see our efforts focused on producing prototypes for our commercial partnerships." 

 

Ilika plc

Graeme Purdy, Chief Executive

Steve Boydell, Finance Director

+44 (0)23 8011 1400

 

 

NUMIS Securities Limited

Oliver Cardigan/ Adrian Trimmings/

James Black

+44 (0) 20 7260 1000

 

Walbrook PR Ltd

+44 (0)20 7933 8780 or ilika@walbrookpr.com

Paul McManus (Media Enquiries)

Mob: +44 (0)7980 541 893

Paul Cornelius (Investor Enquiries)

Mob: +44 (0)7827 879 460

CEO's Statement

Review of Period

 

A World First for Ilika: Solid State Battery Technology

 

2014 started with the exciting announcement that Ilika had achieved a unique and simple methodology for producing a stacked solid state battery that is likely to lead to significant out-licensing opportunities for the Company. It was explained that solid state batteries are currently available, but are restricted to very small capacities, limiting their commercial relevance and market opportunity. Ilika's innovation enables its commercial partners to make larger batteries suitable for mainstream battery applications, including consumer electronics.

 

Electrochemical testing of the stacked cells was completed in Q1 2014, confirming that Ilika's proprietary process had generated performance data that validates the stacked architecture, with two-cell stacks producing twice the voltage and power of a single cell. Further work then proceeded to increase the cross sectional area of the cells in order to make prototype batteries suitable for initial commercialisation in wireless sensor networks, as part of the "Internet of Things".

 

By July 2014, Ilika was able to announce that it had achieved a 25x increase in battery size, making the batteries on a footprint relevant for commercial applications in wireless sensor networks (WSN) and wearables.

 

Pilot Line Commissioning

The next step was to complete the fabrication of a pilot line to allow the production of sufficient quantities of prototype batteries to allow commercial validation by chosen OEM partners. The pilot line produces batteries on a substrate which has a diameter of 15cm (6"), which is an area approximately 20 x larger than that used to initially develop the battery.

 

In September 2014, the Company announced it had signed off the factory acceptance test (FAT) of the pilot line. The next step was to disassemble the line, pack it and ship it to its destination in Southampton. This shipping process was successfully completed and it was re-assembled in time for an official opening in November 2014 by the Rt. Hon. Greg Clark MP, Minister for Science, Education and Cities.

 

At the time of issuing this half yearly report, the pilot line has substantially completed its site acceptance test (SAT). Official sign off is awaiting the delivery of a number of non-critical items included in the delivery scope of the principal system fabricator. The SAT has involved the production of the key materials making up a solid state battery. In particular, the battery production team has successfully deposited a functioning cathode over the complete 176 cm2 area of the standard 6" substrate. The batteries required for WSN and wearable applications will be made by masking (dividing up) this 176 cm2 area. In addition, the pilot line has been demonstrated to deposit materials 5x faster than Ilika's development workflow and a further doubling of that rate is expected to be achievable. This deposition rate has ensured that the batteries can be made at a price point that is commercially attractive on the industrial scale. Production cost models developed together with OEM's interested in Ilika's technology have demonstrated that the batteries can offer the expected technical benefits at a price point below incumbent technology.

 

Intellectual Property Reinforcement

Clearly, the successful execution of Ilika's business model requires a robust and comprehensive IP portfolio that can be licensed as a package. Hence, it was reassuring that in May 2014, the grant of two British patent applications jointly filed with Toyota was confirmed. These patents contained methodology for producing solid state batteries.

 

Commercial Progress

The commercialisation strategy for this technology involves three phases of engagement:

· optimisation of the battery architecture for specific applications

· validation and integration of the batteries into application systems

· technology transfer and licensing for manufacture

 

In the current financial year, the emphasis is on the first of these phases and therefore the announcement in July of a proof of concept contract with a European customer was an important indicator that this strategy was on track.

 

In October 2014, the announcement of the appointment of Keith Jackson, CTO of Meggitt plc, as Non-Executive Director was further evidence that the Company is preparing itself for commercialisation activities.

 

Portfolio Progress

Although the solid state battery programme makes up the majority of Ilika's technology development activities, the Company has a well-defined portfolio of opportunities at various stages of maturity.

 

One of the most advanced of these programmes is the commercialisation of platinum-free fuel cell catalysts. The Carbon Trust in 2012 funded the development of these catalysts through an equity investment. The Company has signed materials transfer agreements and delivered samples of the catalyst for confirmatory testing to OEMs in the USA, Japan and Europe. Initial feedback is encouraging and further testing is expected in this financial year. Post period end, Ilika received the news that its patent in Europe had not been opposed by any third parties in the statutory 9-month period after grant, resulting in Ilika having granted patents covering fuel cell catalyst technology in the USA, Japan and Europe.

 

An early stage technology programme at Ilika is the development of aerospace alloys. Ilika has announced collaborations with Rolls Royce and Boeing. Rolls Royce is interested in high temperature superalloys for use in aerospace engines, while Boeing is focused on high entropy alloys for deployment in aircraft structures. The Rolls Royce programme is supported by a £1.33 million grant from Innovate UK over a three year period, which started in April 2014.

 

Outlook

2015 promises to be an exciting year for Ilika, particularly for tackling the next steps in the development of the Company's solid state battery programme. Investors can expect to see announcements regarding both technical and commercial progress associated with the production of prototypes and the Company developing commercial relationships with OEM partners. The management team remains committed to bringing its technology programmes to successful conclusions to deliver attractive returns to its shareholders.

 

 

 

Graeme Purdy, CEO

 

Ilika plc

 

 

Consolidated statement of comprehensive income for the six months ended 31 October 2014

 

Unaudited Six months ended

31 Oct 2014

Unaudited Six months ended

31 Oct 2013

Audited Year

ended

30 Apr 2014

Notes

£

£

£

Revenue

606,328 

612,999

1,049,879 

Cost of sales

(339,458)

(345,894)

(586,869)

Gross profit

266,870 

267,105

463,010 

Administrative expenses

(1,866,561)

(1,781,279)

(3,569,696)

Other operating income

809

810 

Operating loss

(1,599,691)

(1,513,365)

(3,105,876)

Financial income

27,080 

10,292

22,131 

Financial expense

(1,513)

(1,513)

Loss before tax

(1,572,611)

(1,504,586)

(3,085,258)

Taxation

167,500 

152,528

287,171

Loss for period/total comprehensive income attributable to owners of parent

 

(1,405,111)

 

(1,352,058)

 

(2,798,087)

Loss per share

2

Basic and diluted

(0.02)

(0.03)

(0.05)

 

The results from the periods shown above are derived entirely from continuing operations.

Consolidated balance sheet as at 31 October 2014

 

Unaudited

Six months ended

31 Oct 2014

Unaudited

Six months ended

31 Oct 2013

Audited

Year

ended

30 Apr 2014

Notes

£

£

£

ASSETS

Non-current assets

Intangible assets

35,192

7,048

793 

Property, plant and equipment

553,246

737,690

607,627 

Total non-current assets

588,438

744,738

608,420 

Current assets

Trade and other receivables

636,454

992,499 

572,304 

Current tax receivable

137,975

113,548 

248,191 

Other financial assets - bank deposits

6,052,336

293,007 

1,776,767 

Cash and cash equivalents

1,202,433

1,129,738 

5,329,967 

Total current assets

8,029,198

2,528,792 

7,927,229 

Total assets

8,617,636

3,273,530 

8,535,649 

Issued capital and reserves attributable to owners of parent

Issued share capital

658,836

499,104 

632,660 

Share premium

17,391,768

9,509,020 

16,082,944 

Capital restructuring reserve

6,486,077

6,486,077 

6,486,077 

Retained earnings

 (16,831,890)

(13,995,750)

(15,426,779)

Total equity

7,704,791

2,498,451 

7,774,902 

LIABILITIES

Current liabilities

Trade and other payables

762,845

625,079 

610,747

Provisions

150,000

150,000 

150,000

Total liabilities

912,845

775,079 

760,747

Total equity and liabilities

8,617,636

3,273,530 

8,535,649

 

 

 

 

 

Consolidated cash flow statement for the six months ended 31 October 2014

 

Unaudited

Six months ended

31 Oct 2014

Unaudited

Six months ended

31 Oct 2013

Audited

Year

ended

30 Apr 2014

£

£

£

Cash flows from operating activities

Loss before taxation

(1,572,611)

(1,504,586)

(3,085,258)

Adjustments for:

Amortisation

4,644 

2,378 

8,632 

Depreciation

190,999 

366,088 

556,795 

Equity settled share based payments

-

15,000 

(Profit)/loss on disposal of plant, property and

equipment

 

-

 

(145)

 

(145)

Net financial income

(27,080)

(8,779)

(20,618)

Operating cash flow before changes in working capital, interest and taxes

(1,404,048)

(1,145,044)

(2,525,594)

Decrease/(increase) in trade and other

receivables

 

(64,150)

 

(414,994)

 

5,200 

Increase /(decrease) in trade and other payables

152,098 

138,433 

116,560 

Cash utilised by operations

(1,316,100)

(1,421,605)

(2,403,834)

Tax received

277,716 

268,980 

269,266 

Net cash flow from operating activities

(1,038,384)

(1,152,625)

(2,134,568)

Cash flows from investing activities

Interest received

27,080 

10,292 

29,390 

Sale of property plant and equipment

1,625 

2,450 

2,450 

Purchase of property, plant and equipment

(177,285)

(377)

(61,021)

(Increase)/ Decrease in other financial assets

(4,275,570)

1,162,085 

(321,675)

Net cash used in investing activities

(4,424,150)

1,174,450 

(350,856)

Cash flows from financing activities

Proceeds from issuance of ordinary share capital

1,335,000 

712,500 

7,716,912 

Share issue costs

-

(3,500)

(300,434)

Capital element of finance leases

-

(7,544)

(7,544)

Interest element of finance leases

-

(1,513)

(1,513)

Net cash from financing activities

1,335,000 

699,943 

7,407,421 

Net (decrease)/ increase in cash and cash equivalents

(4,127,534)

721,768 

4,921,997 

Cash and cash equivalents at the start of the period

5,329,967 

407,970 

407,970 

Cash and cash equivalents at the end of the period

1,202,433 

1,129,738 

5,329,967 

 

Consolidated statement of changes in equity (unaudited)

 

 

 

Share capital

Share premium account

Capital

restructuring reserve

 

Retained earnings

 

 

Total

£

£

£

£

£

As at 30 April 2013

475,354

8,823,770 

6,486,077 

(12,643,692)

3,141,509 

Issue of shares

23,750

685,250 

-

709,000

Loss and total

comprehensive income

 

-

 

 

 

(1,352,058)

 

(1,352,058)

As at 31 October 2013

499,104

9,509,020 

6,486,077 

(13,995,750)

2,498,451 

Issue of shares

133,556

6,874,357 

-

7,007,913 

Expenses of share issue

(300,433)

-

(300,433)

Share based payment

-

-

-

15,000

15,000 

Loss and total

comprehensive income

 

-

 

-

-

 

(1,446,029)

 

(1,446,029)

As at 30 April 2014

632,660

16,082,944 

6,486,077 

(15,426,779)

7,774,902 

Issue of shares

26,176

1,308,824 

-

1,335,000 

Loss and total

comprehensive income

 

-

 

-

 

 

(1,405,111)

 

(1,405,111)

As at 31 October 2014

658,836

17,391,768 

6,486,077 

(16,831,890)

7,704,791 

 

Share capital

The share capital represents the nominal value of the equity shares in issue.

 

Share premium account

When shares are issued, any premium paid above the nominal value is credited to the share premium reserve.

 

Retained earnings

The retained earnings reserve records the accumulated profits and losses of the Group since inception of the business.

 

Capital restructuring reserve

The capital restructuring reserve arises on the accounting for the share for share exchange. It represents the difference between the value of the issued equity instruments of Ilika Technologies Limited immediately before the share for share exchange and the equity instruments of Ilika plc along with the shares issued to effect the share for share exchange.

 Notes to the consolidated financial statements

 

1. Accounting policies

 

Basis of preparation

 

The interim financial statements, which are unaudited, have been prepared on the basis of accounting policies consistent with International Financial Reporting Standards ("IFRSs") adopted by the European Union. The accounting policies are the same as applied in the Group's latest financial statements.

 

The interim financial statements do not include all of the information required for full annual financial statements and do not comply with all the disclosures in IAS 34 'Interim Financial Reporting'. Accordingly, whilst the interim financial statements have been prepared in accordance with IFRS they cannot be construed as being in full compliance with IFRS.

 

The financial information for the year ended 30 April 2014 does not constitute the full statutory accounts for that period. The Annual Report and Accounts for 30 April 2014 have been filed with the Registrar of Companies. The Independent Auditors' Report on the Annual Report and Accounts for 2014 was unqualified and did not include references to any matters which the auditors drew attention by way of emphasis without qualifying their report and did not contain statements under Section 498(2) or 498(3) of the Companies Act 2006.

 

Going concern

 

The financial statements are prepared on a going concern basis which the directors believe continues to be appropriate. The Group meets its day-to-day working capital requirements through existing cash resources which, at 31 October 2014, amounted to £7,254,769. The directors have prepared projected cash flow information for the period ending twelve months from the date of their approval of these financial statements. On the basis of this cash flow information the directors believe that the Group will be able to continue to trade for the foreseeable future.

 

2. Loss per share

 

Loss per ordinary share have been calculated using the weighted average number of shares in issue during the relevant financial periods. The weighted average number of equity shares in issue and the earnings, being loss after tax, are as follows:

 

Unaudited

Six months ended

31 Oct 2014

Unaudited

Six months ended

31 Oct 2013

Audited

Year

ended

30 Apr 2014

Number

Number

Number

Weighted average number of equity shares

65,626,980 

49,691,004 

52,153,675

£

£

£

Loss, being loss after tax

(1,405,111)

(1,352,058)

(2,798,087)

 

The loss attributable to ordinary shareholders and weighted average number of ordinary shares for the purpose of calculating the diluted earnings per ordinary share are identical to those used for basic earnings per share. This is because the exercise of share options and warrants would have the effect of reducing the loss per ordinary share and is therefore not dilutive under the terms of IAS 33.

 

- Ends -

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR FMGZMVMKGKZM
Date   Source Headline
13th May 202410:16 amRNSPosting of Circular & Notice of General Meeting
10th May 20243:02 pmRNSResult of Placing
10th May 20247:00 amRNSProposed Placing and Open Offer & Notice of GM
26th Apr 20247:00 amRNSAgratas joins Goliath industrialisation programme
23rd Apr 20247:00 amRNSCapital Markets Day and Trading Update
27th Mar 20247:00 amRNSNotice of Capital Markets Day and Investor Q&A
23rd Jan 20247:00 amRNSHalf-year Report
15th Jan 20247:00 amRNS2024 Conference Schedule
14th Dec 20231:46 pmRNSAward of Share Options, Exercise of Options & TVR
13th Dec 20231:43 pmRNSHolding(s) in Company
6th Dec 20237:00 amRNSLithium-ion parity development milestone
24th Nov 20237:00 amRNSTrading Update, Notice of Results & Presentations
20th Nov 20237:00 amRNSKey Technology Development Milestone
9th Oct 20237:00 amRNSAward of Scale-up Grant Funding for Goliath
20th Sep 20233:20 pmRNSResult of AGM & Award of Executive Share Options
18th Aug 20237:00 amRNSPosting of Annual Report and Notice of AGM
4th Aug 20237:00 amRNSSigned agreement with Cirtec Medical
13th Jul 20237:00 amRNSFinal Results
16th Jun 20237:00 amRNSSenior appointment&conversion of preference shares
22nd May 20237:00 amRNSTrading Update & Notice of Results
11th May 20237:00 amRNSFirst Customer Shipments of Stereax M300 Batteries
26th Apr 20237:00 amRNSExercise of Options and Total Voting Rights
11th Apr 20237:00 amRNSFirst Customer Shipment of Stereax® Batteries
8th Mar 20234:35 pmRNSPrice Monitoring Extension
1st Mar 20237:00 amRNSAward of Share Options
31st Jan 202310:30 amRNSDirector/PDMR Shareholding
30th Jan 20232:05 pmRNSSecond Price Monitoring Extn
30th Jan 20232:00 pmRNSPrice Monitoring Extension
30th Jan 202311:05 amRNSSecond Price Monitoring Extn
30th Jan 202311:00 amRNSPrice Monitoring Extension
26th Jan 20232:05 pmRNSSecond Price Monitoring Extn
26th Jan 20232:00 pmRNSPrice Monitoring Extension
26th Jan 202311:05 amRNSSecond Price Monitoring Extn
26th Jan 202311:00 amRNSPrice Monitoring Extension
26th Jan 20239:05 amRNSSecond Price Monitoring Extn
26th Jan 20239:00 amRNSPrice Monitoring Extension
26th Jan 20237:00 amRNSAward of Grant Funding for Goliath
19th Jan 20237:00 amRNSHalf-year Report
16th Jan 20237:00 amRNSMOU signed with Cirtec Medical
9th Jan 20234:40 pmRNSSecond Price Monitoring Extn
9th Jan 20234:35 pmRNSPrice Monitoring Extension
28th Dec 20224:40 pmRNSSecond Price Monitoring Extn
28th Dec 20224:35 pmRNSPrice Monitoring Extension
28th Dec 20222:05 pmRNSSecond Price Monitoring Extn
28th Dec 20222:00 pmRNSPrice Monitoring Extension
19th Dec 20224:40 pmRNSSecond Price Monitoring Extn
19th Dec 20224:35 pmRNSPrice Monitoring Extension
16th Dec 20224:40 pmRNSSecond Price Monitoring Extn
16th Dec 20224:35 pmRNSPrice Monitoring Extension
21st Nov 20221:29 pmEQSIlika 'well positioned' to deliver battery product combination

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.